Eargo and hearX Close Merger, Announce New Combined Company, LXE Hearing
- Two national hearing health brands combine to make high-quality hearing aids more accessible and affordable for the estimated 44 million American adults with hearing loss
- First notable merger in the over-the-counter hearing aid space since the FDA's 2022 regulations that allowed for the sale of over-the-counter hearing aids
- The new company will receive
$100 million in funding from Patient Square Capital, a dedicated health care investment firm
LXE Hearing will operate as one company with its two established consumer hearing aid brands, Eargo and
LXE Hearing is grounded in clinical excellence, drawing on both companies' exceptional clinical standards and scientific research, with more than 52 peer-reviewed articles validating the technology along with 68 patents.
hearX CEO and co-founder
"The merger between Lexie and Eargo is founded on our shared mission to create hearing health solutions for everyone, everywhere," said Klopper. "Eargo's cutting-edge design, emphasis on clinical quality and customer-first approach to service perfectly complement hearX's suite of Bose-powered products and its award-winning mobile app. Together, we are going to revolutionize hearing aids and hearing health."
Eargo is recognized as a pioneer in direct-to-consumer hearing aids in the
"hearX and
Patient Square Capital, a dedicated health care investment firm that invests in high-quality, growth-oriented health care companies, is backing the deal with an additional
"The vast majority of American adults who suffer from hearing loss currently do not use hearing aids given historical barriers to access and shortcomings with traditional offerings," said
For more information about LXE Hearing, please visit www.lxehearing.com.
Advisors
Lazard acted as sole financial advisor to hearX on the merger and capital raise. Ropes & Gray LLP acted as legal counsel to Patient Square Capital and Eargo.
About Eargo
Eargo is a medical device company on a mission to improve hearing health. Our innovative products and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility, and cost. We believe our Eargo hearing aids are the first virtually invisible, rechargeable, complete-in-canal, FDA-regulated devices indicated to compensate for mild to moderate hearing loss. Eargo's differentiated, consumer-first approach empowers consumers to take control of their hearing. Consumers can purchase online, at retail locations or over the phone and get personalized and convenient consultation and support from hearing professionals via phone, text, e-mail or video chat. Eargo hearing aids are offered to consumers OTC without compromising the features, performance or support that we believe is vital to successfully integrating devices into our customers' lives. To learn more, please visit https://www.eargo.com/.
About hearX Group
hearX www.hearxgroup.com is an industry-leading health technology company, with a suite of digital, clinically-validated, affordable and mobile technologies for hearing loss detection and diagnosis, for those who need it most. Founded in 2015, hearX technologies are now used in over 70 countries globally for early detection and intervention.
About Lexie Hearing
About Patient Square Capital
Patient Square Capital is a dedicated health care investment firm with approximately
1*Source: Circana, LLC, Retail Tracking Service, US Dollar and Unit Sales,
View original content to download multimedia:https://www.prnewswire.com/news-releases/eargo-and-hearx-close-merger-announce-new-combined-company-lxe-hearing-302415915.html
SOURCE LXE Hearing
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Getty Images in talks with lenders on rescue financing - report
- Fuse Oncology and Associated Medical Professionals of NY Launch Proof of Concept for End-to-End Radiation Oncology Workflow in Urology
- Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque P
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Lazard, Definitive Agreement, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share